PLRZ Overview

Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers..

Wall Street analysts forecast PLRZ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLRZ is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Polyrizon Ltd revenue for the last quarter amounts to NaN USD, decreased

Polyrizon Ltd. EPS for the last quarter amounts to USD, decreased

Polyrizon Ltd (PLRZ) has 1 emplpoyees as of March 12 2026.

Today PLRZ has the market capitalization of 13.36M USD.